Monopar Therapeutics
MNPR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MNPR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MNPR
Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company focused on late-stage ALXN1840 for Wilson disease and radiopharmaceutical programs including MNPR-101-Zr and MNPR-101-Lu for advanced cancers.
Key risk: No approved therapeutic products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials for Monopar Therapeutics.
Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company focused on late-stage ALXN1840 for Wilson disease and radiopharmaceutical programs including MNPR-101-Zr and MNPR-101-Lu for advanced cancers.
- Monopar is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease and radiopharmaceutical programs, including MNPR-101-Zr and MNPR-101-Lu [sec_mda · as of 2026-08-12].
- As of 2026-06-30, the company reported cash & equivalents of $52.8M, total revenue of $0.0M, net income of -$5.3M, and shareholders' equity of $137.8M [sec].
- Management has extensive experience, with companies they co-founded achieving four drug approvals and three diagnostic medical imaging device approvals in the U.S. and the EU [sec_mda · as of 2026-08-12].
- The company has not completed development through marketing approvals of any therapeutic products and expects to continue incurring significant operating losses [sec_mda · as of 2026-08-12].
- Future capital requirements depend on factors including the development program for ALXN1840, clinical progress of MNPR-101-Zr and MNPR-101-Lu, and preclinical activities [sec_mda · as of 2026-08-12].
What works
- Management team has extensive experience in developing therapeutics and medical technologies through global regulatory approval and commercialization, with a track record of four drug approvals and three diagnostic medical imaging device approvals [sec_mda · as of 2026-08-12].
- The company has a late-stage asset, ALXN1840, for Wilson disease, which is a potentially high-value indication with significant unmet need [sec_mda · as of 2026-08-12].
- Monopar is advancing radiopharmaceutical programs (MNPR-101-Zr and MNPR-101-Lu) in advanced cancers, a rapidly growing therapeutic area [sec_mda · as of 2026-08-12].
What to weigh
- The company has not completed development through marketing approvals of any therapeutic products and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-08-12].
- Monopar may need to raise additional funding or find suitable pharmaceutical partners to continue advancing its clinical programs and support preclinical studies [sec_mda · as of 2026-03-27].
- The company is unable to accurately estimate the amounts and timing of required capital outlays due to dependence on multiple factors, including development and commercialization efforts [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Monopar is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease and radiopharmaceutical programs.
“We are a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs, including MNPR-”
SEC MD&A · August 12, 2026
Management has achieved four drug approvals and three diagnostic medical imaging device approvals.
“In aggregate, companies they co-founded have achieved four drug approvals and three diagnostic medical imaging device approvals in the U.S. and the EU”
SEC MD&A · August 12, 2026
The company has not completed development through marketing approvals of any therapeutic products.
“As a company, we have not completed development through marketing approvals of any therapeutic products.”
SEC MD&A · August 12, 2026
Future capital requirements depend on development programs for ALXN1840, MNPR-101-Zr, and MNPR-101-Lu.
“Our future capital requirements will depend on many factors, including: | | ● | the development program for ALXN1840 in Wilson disease and, if it is approved, commercialization efforts; | | --- | --- | --- | | | | | | | ● | the clinical development progress of MNPR-101-Zr in imaging advanced cancers; | | | | | | | ● | the clinical development progress of MNPR-101-Lu as a therapeutic agent in advanced cancers;”
SEC MD&A · August 12, 2026
Risks & what to watch (3)›
Key risks
- No approved therapeutic products — The company has not completed development through marketing approvals of any therapeutic products and expects significant operating losses [sec_mda · as of 2026-08-12].
- Need for additional funding — Monopar may need to raise additional funding or find partners to advance clinical programs and support preclinical studies [sec_mda · as of 2026-03-27].
- Uncertain capital requirements — The company cannot accurately estimate the amounts and timing of required capital outlays due to dependence on multiple factors [sec_mda · as of 2026-08-12].
What to watch
- Progress of the ALXN1840 development program for Wilson disease, including any regulatory milestones [sec_mda · as of 2026-08-12].
- Clinical development progress of MNPR-101-Zr in imaging advanced cancers [sec_mda · as of 2026-08-12].
- Clinical development progress of MNPR-101-Lu as a therapeutic agent in advanced cancers [sec_mda · as of 2026-08-12].
- Any updates on the company's ability to raise additional funding or secure pharmaceutical partnerships [sec_mda · as of 2026-03-27].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Monopar Therapeutics through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Monopar Therapeutics facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
103.1 months
D/E 0.03
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$397.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 2,634,820 | $144.1M |
| ra capital management, l.p. | 667,207 | $36.6M |
| vanguard capital management llc | 436,926 | $23.9M |
| deerfield management company, l.p. | 323,745 | $17.7M |
| blackrock, inc. | 316,567 | $17.3M |
| adage capital partners gp, l.l.c. | 309,195 | $16.9M |
| adar1 capital management, llc | 264,278 | $14.5M |
| polar capital holdings plc | 226,526 | $12.4M |
| vivo capital, llc | 181,000 | $9.9M |
| wellington management group llp | 174,342 | $9.6M |
Showing top 10 of 79 institutional holders of Monopar Therapeutics. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 67.1%
- Days to cover
- 9.0
- Shares short
- 1,684,127
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MNPR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Monopar Therapeutics?
Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company focused on late-stage ALXN1840 for Wilson disease and radiopharmaceutical programs including MNPR-101-Zr and MNPR-101-Lu for advanced cancers.
What is Monopar Therapeutics's lead drug candidate?
Monopar Therapeutics's most advanced tracked candidate is alxn1840 (Phase 3) for Wilson disease.
Who is the CEO of Monopar Therapeutics?
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. is the chief executive officer of Monopar Therapeutics (MNPR).
Where is Monopar Therapeutics headquartered?
Monopar Therapeutics (MNPR) is headquartered in Wilmette, IL, United States.
What therapeutic areas does Monopar Therapeutics focus on?
Monopar Therapeutics develops therapies across Oncology, Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.